Apisarnthanarak et al.30 (2020). |
4 |
Tailândia |
160 (59,0) |
32 (23-62). |
GAD-7 (Min: 0-4; L:5-9; M:10-14: G>14. |
T: 68 (42,5%)/ L: 37 (23,1%)/ M: 23 (14,4%)/ G: 8 (5%). |
Badahdah et al.31 (2020). |
3 |
Omã |
509 (80,3) |
37.67±7.68. |
GAD-7 (Min: 0-4, L: 5-9; M: 10-14; G:15-21). |
T: 64,7%/ L: 38,7%/ M: 17,7%/ G: 8,3%. |
Chatterjee et al.32 (2020). |
3 |
Índia |
152 (21,7) |
42.05±12.19. |
DASS-21 (NI). |
T: 60 (39,5%)/ L: 11 (7,2%)/ M: 27 (17,8%); G: 10 (6,6%)/ EG: 11 (7,2%). |
Chen et al.33 (2020). |
3 |
China |
105 (90,5) |
32.6±6.5. |
SAS (L:50-59; M: 60-69; G ≥70). |
T: 19 (18,1%)/ L: 11 (10,5%) M: 6 (5,7%)/ G: 2 (1,9%). |
Chew et al34 (2020). |
5 |
Singapura e Índia |
906 (64,3) |
29 (25-35). |
DASS-21 (>7, L: 8-9; M: 10-14; G: 15-19; EG: 20-42). |
T: 142 (15,7%)/ L: 63 (7,0%)/ M: 61 (6,7%)/ G: 9 (1,0%). EG: 9 (1,0%). |
Civantos et al.35 (2020). |
4 |
Estados Unidos |
349 (39,3) |
26-30: 26,9%; 31-35: 32,7%; 36-40: 12,6%; >40: 27,8%. |
GAD-7 (N:0-4; L: 5-9; M: 10-14; G: 15-21). |
T: 167 (47,9%)/ L: 101 (28,9%)/ M: 40 (11,5%)/ G: 26 (7,4%). |
Consolo et al.36 (2020). |
4 |
Itália |
356 (39,6) |
<35: 16,6%; 35-55: 48,6%; >55: 34,8%. |
GAD-7 (Min:0-4; L:5-9; M: 10-14; G: 15-21). |
T: 57,2% / L: 33,3%/ M: 15,2%/ G: 8,7%. |
Corbett et al.37 (2020). |
2 |
Irlanda |
240 (NI para todos) |
18-25: 9; 25-40: 110; 40-50: 64; 50-60: 50; >60: 7. |
GAD-7 (NI). |
T (M e G): 21,0%. |
Dal’Bosco et al.38 (2020). |
4 |
Brasil |
88 (89,8) |
21-30: 42,0%; 31-40: 36,4%; >40: 21,6%. |
HAD (>8). |
T: 43 (48,9%). |
Du et al.39 (2020). |
2 |
China |
134 (60,5) |
≥35: 68; 18-34: 66. |
BAI (≥8). |
T: 28 (20,9%). |
Elbay et al.40 (2020). |
3 |
Turquia |
442 (56,8), |
36.05±8.69. |
DASS-21 (NI). |
T: 224 (51,6%)/ L: 16,3%/ M: 13,1%/ G: 10,6%/ EG: 11,5%. |
Gupta et al.41 (2020). |
4 |
Nepal |
150 (42,7), |
29.5±6.1. |
GAD-7 (N:0-4; L:5-9; M: 10-14; M-G:15-19 e G≥15). |
T: 56 (37,3%)/ L: 41 (27,3%), M: 12 (8,0%)/ M-G: 2 (1,3%)/ G: 1 (0,7%). |
Hu et al.42 (2020). |
4 |
China |
2,014 (87,1) |
30.99±6.17. |
SAS (L: 50-59; M: 60-69; G: 70). |
T: 41,4%/ L: 545 (27,1%)/ M: 221 (11,0%)/ G: 67 (3,3%). |
Huang et al.43 (2020). |
4 |
China |
230 (81,3) |
20 a 59. |
SAS (≥50). |
T: 53 (23,04%)/ L: 37 (16,09%)/ M: 11 (4,78%)/ G: 5 (2,17%). |
Lai et al.44 (2020). |
5 |
China |
1257 (76,7) |
18->40. |
GAD-7 (≥5). |
T: 560 (44,6%)/ L: 406 (32,3%)/ M: 88 (7,0%)/ G: 66 (5,3%) |
Lin et al.45 (2020). |
4 |
China |
2,316 (NI) |
NI. |
GAD-7 (≥5). |
T: 952 (41,1%). |
Liu et al.46 (2020). |
5 |
China |
512 (84,57) |
18 a 39. |
SAS (≥50). |
T: 64 (12,5%)/ L: 53 (10,35%)/ M: 7 (1,36%)/ G: 4 (0,78%). |
Lu et al.47 (2020). |
5 |
China |
2,299 (77,6) |
<30 a >50. |
HAMA (L e M: 7-13; G: ≥14). |
T: 569 (24,8%)/ G: 63 (2,7%) |
Moghadasi et al.48 (2020). |
3 |
Irã |
14 (50) |
40.58±4.44. |
BAI (NI). |
T: 2 (14,3%) |
Naser et al.49 (2020). |
4 |
Jordânia |
1163 (56,1) |
18 a >50. |
GAD-7 (≥5). |
T: 823 (70,8%)/ L: 442 (38,0%)/ M: 250 (21,5%)/ G: 131 (11,3%). |
Que et al.50 (2020). |
5 |
China |
2285 (69,1) |
31.06±6.9. |
GAD-7 (L:5-9; M:10-14; G≥15). |
T: 46,0%/ L: 787 (34,44%)/ M-G: 265 (11,60%). |
Rossi et al.51 (2020). |
4 |
Itália |
1379 (77,2) |
39.0±16.0. |
GAD-7 (G≥15). |
T: 273 (19,8%). |
Shechter et al.52 (2020). |
3 |
Estados Unidos |
657 (70,9) |
18-24: 1,5%; 25-34:46,8%; 35-44:20,9%; 45-54:12,0%; 55-64: 8,9%; 65-74: 0,4%; ≥75: 0,3%); NI: 5 (0,7%). |
GAD-2 (≥3). |
T: 33,0%. |
Tan et al.53 (2020). |
4 |
Singapura |
470 (68,3) |
31 (28-36). |
DASS-21 (>7). |
T: 68 (14,5%). |
Temsah et al.54 (2020). |
5 |
Arábia Saudita |
582 (75,1) |
≤30: 30,6%; 31-39: 38,3%; 40-49: 22,9%; ≥50: 8,2%. |
GAD-7 (L<5; M (ponto de corte):5-9; M alta: 10-14; muito alta: 10-14. |
T: 185 (31,8%)/ M: (>5 com ansiedade): 121 (20,8%)/ M alta: 47 (8,1%)/ muito alta: 17 (2,9%). |
Vanni et al.55 (2020). |
4 |
Itália |
46 (65,2) |
47 (40-54). |
DASS-21 (N:0-7; L:8-9; M:10-14; G:15-19). |
T: 18 (39,1%)/ L-M: 12 (26,1%)/ G-EG: 6 (13,0%). |
Wang et al.56 (2020). |
5 |
China |
123 (90) |
33.75±8.41. |
SAS (≥50). |
T: 9 (7%). |
Xiao et al.57 (2020). |
5 |
China |
958 (68,2) |
NI. |
HAD (≥8). |
T: 518 (54,1%). |
Yang et al.58 (2020). |
5 |
Coreia do Sul |
65 (47,7) |
20-29: 21; 30-39: 20: 40-49: 16; >50: 8. |
GAD-7 (≥5). |
T: 21 (32,3%). |
Zandifar et al.59 (2020). |
2 |
Irã |
N: 894 (SF: 619; SM: 254) |
>30: 293; 30-40: 364; >40: 205. |
DASS-21 (NI). |
T: 51,2%. |
Zhang et al.60 (2020). |
4 |
China |
1.563 (82,7) |
18 a 60. |
GAD-7 (≥5). |
T: 699 (44,7%)/ L: 497 (31,8%)/ M: 119 (7,6%)/ G: 83 (5,3%). |
Zhang et al.61 (2020). |
2 |
Irã |
304 (58,6) |
35.1±9.1. |
PHQ-4/GAD-2 (NI). |
T: 28,0%. |
Zhang et al.62 (2020). |
4 |
China |
2.182 (64,2) |
<18 a >60. |
GAD-2 (≥3) |
T: 228 (10,4%) |
Zhao e Huang63 (2020). |
4 |
China |
2.250 (NI) |
NI |
GAD-7 (≥9). |
T: 802 (35,6%). |
Zhu et al.64 (2020). |
4 |
China |
5.062 (85,0) |
19 a 49 |
GAD-7 (≥8). |
T: 1218 (24,1%). |
Zhu et al.65 (2020). |
5 |
China |
165 (83,0) |
34.16±8.06. |
SAS (≥50). |
T: 33 (20,0%). |